Chen Chao, Yin Jingjing, Wang Wei, Zhao Danqing, Wei Chong, Jia Congwei, Zhang Wei, Zhou Daobin, Zhang Yan
Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Department of Hematology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.
BMC Cancer. 2025 Jul 24;25(1):1204. doi: 10.1186/s12885-025-14634-7.
Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare subtype of cutaneous lymphoma, and the standard of care for SPTCL has not been well-defined. This retrospective study analyzed the efficacy of the CHOP-regimen in newly-diagnosed SPTCL patients in China. The study reviewed 32 SPTCL patients treated at Peking Union Medical College Hospital over the last two decades. The median age of these patients was 27 years. Among them, 56.3% were female. Sixteen patients had a PIT score ≥ 2, and 28.1% patients had concurrent hemophagocytic lymphohistiocytosis. Histopathology typically showed a lobular panniculitis with individual adipocytes surrounded by atypical lymphocytes, usually with a CD3, CD4, CD8, CD56 phenotype. Twenty-eight patients (87.5%) received CHOP-like regimen as the first-line treatment. The ORR and CR rate of induction therapy were only 42.9% and 35.7%, respectively. The median PFS and OS were 3.2 months and 147.5 months. Factors, concurrent HLH and PIT ≥ 2, were indicators of shorter PFS in univariate analysis. This study showed that CHOP-like regimen was inadequate as a first-line treatment for SPTCL, emphasizing the need for alternative therapeutic strategies.
皮下脂膜炎样T细胞淋巴瘤（SPTCL）是皮肤淋巴瘤的一种罕见亚型，SPTCL的标准治疗方案尚未明确界定。这项回顾性研究分析了CHOP方案对中国新诊断的SPTCL患者的疗效。该研究回顾了过去二十年在北京协和医院接受治疗的32例SPTCL患者。这些患者的中位年龄为27岁。其中，56.3%为女性。16例患者的PIT评分≥2，28.1%的患者并发噬血细胞性淋巴组织细胞增生症。组织病理学表现通常为小叶性脂膜炎，单个脂肪细胞被非典型淋巴细胞包围，通常具有CD3、CD4、CD8、CD56表型。28例患者（87.5%）接受CHOP样方案作为一线治疗。诱导治疗的ORR和CR率分别仅为42.9%和35.7%。中位PFS和OS分别为3.2个月和147.5个月。在单因素分析中，并发HLH和PIT≥2是PFS较短的指标。这项研究表明，CHOP样方案作为SPTCL的一线治疗并不充分，强调需要替代治疗策略。
